OptimizeRx (OPRX) AI Stock Analysis

• Market Cap: $351.62M
• Dividend Yield: N/A
• Average Volume (3M): 309.32K
• Price to Earnings (P/E): ―
• Beta (1Y): 2.14
• Revenue Growth: 24.19%
• EPS Growth: N/A
• Country: US
• Employees: 128
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Healthcare Information Services
• EPS (TTM): 0.20
• Shares Outstanding: 18,565,033
• 10 Day Avg. Volume: 321,860
• 30 Day Avg. Volume: 309,323
• PEG Ratio: -0.65
• Price to Book (P/B): 0.76
• Price to Sales (P/S): 0.97
• P/FCF Ratio: 18.61
• Enterprise Value/Market Cap: 0.00
• Enterprise Value/Revenue: 0.00
• Enterprise Value/Gross Profit: 0.00
• Enterprise Value/Ebitda: 0.00
• 1Y Price Target: $25.80
• Price Target Upside: 64.86% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 6
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 58 Neutral
• Price Target: $16.50 ▲(5.43% Upside)

OptimizeRx's overall stock score reflects a mix of strong revenue growth and operational improvements, as highlighted in the earnings call, but is weighed down by technical indicators showing bearish momentum and a challenging valuation due to negative profitability. The company's financial performance shows potential, but profitability and technical trends need improvement for a higher score.

Positive Factors

Revenue Growth

The 22% YoY revenue growth in Q3 indicates strong market demand and successful product adoption, supporting long-term business expansion.

Gross Margin Expansion

Improved gross margins reflect efficient cost management and economies of scale, enhancing profitability potential over time.

Debt Reduction

Accelerated debt reduction strengthens the balance sheet, reducing financial risk and improving long-term financial flexibility.

Negative Factors

Profitability Challenges

Ongoing profitability issues, with negative net income and EBIT margins, could hinder long-term financial sustainability and growth.

Operating Expenses

Rising operating expenses from variable compensation can strain margins, impacting operational efficiency and financial performance.

Flat Revenue Growth Expectations

Flat revenue growth expectations for Q4 may indicate market saturation or competitive pressures, affecting future growth prospects.

OptimizeRx Business Overview & Revenue Model

Company Description

OptimizeRx (OPRX) is a healthcare technology company that operates in the digital health sector, focusing on improving patient outcomes through its innovative platform. The company provides a suite of solutions designed to enhance patient access to medications and streamline communication between healthcare providers, patients, and pharmaceutical companies. OptimizeRx's core products include electronic health record (EHR) integrations that facilitate the delivery of patient savings programs and medication information directly within the clinical workflow, thereby enhancing the prescribing process and adherence to treatment regimens.

How the Company Makes Money

OptimizeRx generates revenue primarily through its digital health platform, which offers services to pharmaceutical companies, healthcare providers, and payers. The company earns money by charging pharmaceutical manufacturers for access to its platform, where they can promote their patient support programs and discounts directly to healthcare providers. Additionally, OptimizeRx monetizes its EHR integrations by providing value-added services that enhance the functionality of electronic health records, driving user engagement and adoption. Partnerships with leading EHR vendors and collaborations with various healthcare stakeholders further contribute to its revenue streams by expanding its market reach and enhancing its service offerings.

OptimizeRx Financial Statement Overview

Summary

OptimizeRx shows positive revenue and cash flow growth, but faces profitability challenges with negative net profit margins. The strong equity position and low leverage provide a stable financial foundation.

Income Statement

OptimizeRx shows a positive revenue growth trend, with a TTM revenue increase of 2.43% compared to the previous year. However, the company is facing profitability challenges, as indicated by negative EBIT and net income margins. The gross profit margin remains strong at 62.97%, but the net profit margin is negative at -16.33%, reflecting ongoing operational inefficiencies.

Balance Sheet

The balance sheet reflects a solid equity position with a debt-to-equity ratio of 0.28, indicating low leverage. The equity ratio is robust at 69.28%, showing a strong capital structure. However, the company has experienced a decline in total assets, which may impact future growth potential.

Cash Flow

OptimizeRx demonstrates a positive trend in cash flow, with a significant increase in free cash flow by 32.12% in the TTM period. The operating cash flow to net income ratio is favorable, indicating efficient cash generation relative to net losses. However, the company needs to maintain this momentum to ensure long-term financial stability.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	104.75M	92.13M	71.52M	62.45M	61.29M	43.31M
Gross Profit	67.45M	59.38M	42.90M	38.97M	35.64M	24.11M
EBITDA	1.04M	-8.90M	-21.31M	-9.42M	2.33M	646.89K
Net Income	-9.87M	-20.11M	-17.57M	-11.44M	378.08K	-2.21M
Balance Sheet
Total Assets	169.26M	171.17M	183.37M	134.65M	140.99M	60.33M
Cash, Cash Equivalents and Short-Term Investments	16.59M	13.38M	13.85M	74.14M	84.68M	10.52M
Total Debt	3.85M	33.19M	36.82M	234.43K	327.71K	448.75K
Total Liabilities	49.98M	54.17M	56.82M	8.54M	9.61M	10.35M
Stockholders Equity	119.28M	117.00M	126.55M	126.11M	131.38M	49.97M
Cash Flow
Free Cash Flow	10.16M	4.78M	-8.11M	10.41M	240.04K	-6.44M
Operating Cash Flow	10.41M	4.89M	-7.24M	10.65M	726.04K	-6.31M
Investing Cash Flow	-340.00K	-450.00K	-25.34M	-58.18M	-486.00K	-124.72K
Financing Cash Flow	-8.45M	-4.91M	28.22M	-18.95M	73.92M	-1.90M

OptimizeRx Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 15.65
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For OPRX, the sentiment is Negative. The current price of 15.65 is below the 20-day moving average (MA) of 19.66, below the 50-day MA of 18.87, and above the 200-day MA of 12.63, indicating a neutral trend. The MACD of -0.15 indicates Positive momentum. The RSI at 34.65 is Neutral, neither overbought nor oversold. The STOCH value of 17.61 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for OPRX.

OptimizeRx Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SPOK	72 Outperform	$283.64M	17.21	10.88%	9.04%	1.47%	11.33%
OMCL	69 Neutral	$1.60B	83.68	1.62%	―	10.67%	―
HSTM	67 Neutral	$734.21M	36.52	5.87%	0.48%	3.68%	5.62%
OPRX	58 Neutral	$351.62M	―	0.03%	―	24.19%	―
TBRG	57 Neutral	$288.37M	-22.76	1.68%	―	3.75%	―
SOPH	57 Neutral	$316.27M	-4.26	-86.09%	―	13.66%	-2.65%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

OptimizeRx Corporate Events

OptimizeRx Earnings Call: Strong Q3 and Upbeat Outlook

The recent earnings call for OptimizeRx Corporation showcased a strong financial performance in the third quarter, marked by significant revenue and EBITDA growth. The company has raised its guidance for the current and upcoming fiscal years, while also making strategic moves to reduce debt. Despite these achievements, the company remains conservative in its expectations for the fourth quarter, citing increased operating expenses due to higher variable compensation. Overall, the sentiment of the call was positive, with a clear focus on sustained growth and operational excellence.

OptimizeRx Reports Strong Q3 Growth and Raises Guidance

OptimizeRx Corporation, headquartered in Waltham, Massachusetts, is a prominent healthcare technology company that specializes in connecting life science brands with patients and healthcare providers through innovative AI-driven tools. The company’s platform facilitates timely and relevant engagement, enhancing healthcare outcomes.

OptimizeRx Announces Leadership Changes for Strategic Growth

On August 19, 2025, OptimizeRx Corporation announced leadership changes aimed at accelerating its strategic growth and achieving the Rule of 40 strategy, which balances sustained growth with increased profitability. Brendan Merrell was appointed as the Chief Operating Officer, while Edward Stelmakh transitioned to the role of Chief Financial & Strategic Officer to lead corporate strategy and financial operations. These changes reflect the company’s commitment to aligning talent and structure with its long-term strategic objectives under CEO Steve Silvestro’s management. The leadership advancements, including the promotion of Andy D’Silva to Chief Business Officer, are designed to enhance the company’s focus on profitable growth and shareholder value creation.

The most recent analyst rating on (OPRX) stock is a Hold with a $18.50 price target. To see the full list of analyst forecasts on OptimizeRx stock, see the OPRX Stock Forecast page.

OptimizeRx Earnings Call: Strong Growth and Positive Outlook

The recent earnings call for OptimizeRx Corporation painted a predominantly positive picture, marked by significant revenue growth, improved financial health, and increased guidance for the coming year. While the company expressed confidence in its strategic positioning and operational excellence, there were some concerns about the sustainability of revenue growth due to reliance on managed services and uncertainties in future revenue predictions. Nonetheless, the positive elements of the call notably outweighed the concerns, leaving investors with an optimistic outlook.

OptimizeRx Reports Strong Q2 2025 Financial Growth

OptimizeRx Corporation, a healthcare technology company based in Waltham, Massachusetts, specializes in connecting life sciences brands with healthcare providers and patients through AI-driven tools. The company recently reported a significant financial improvement for the second quarter of 2025, showcasing a 55% increase in revenue to $29.2 million and a 59% rise in gross profit to $18.6 million year-over-year.